tetano
Editor, Senior Moderator
Thromb Res
. 2020 Nov 5;197:65-68.
doi: 10.1016/j.thromres.2020.10.031. Online ahead of print.
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort
Lei Lynn[SUP] 1 [/SUP], Juan A Reyes[SUP] 2 [/SUP], Katrina Hawkins[SUP] 3 [/SUP], Arjun Panda[SUP] 4 [/SUP], Laura Linville[SUP] 4 [/SUP], Walaa Aldhahri[SUP] 4 [/SUP], Ghazal Kango[SUP] 5 [/SUP], Sneha Shah[SUP] 4 [/SUP], Shant Ayanian[SUP] 5 [/SUP], Karolyn Teufel[SUP] 5 [/SUP]
Affiliations
Abstract
Background: COVID-19 infection is associated with D-dimer elevations, high rates of thrombus formation, and poor clinical outcomes. We sought to determine if empiric therapeutic anticoagulation (AC) affected survival in COVID-19 patients compared to standard prophylactic AC.
Methods: Retrospective analysis of 402 COVID-19 patients hospitalized between March 15 and May 31, 2020 was performed. Clinical outcomes were compared between 152 patients treated with therapeutic AC to 250 patients on prophylactic AC. An elastic net logistic regression was designed to first identify the important variables affecting mortality. These variables were then included as covariates to AC in standard multivariate logistic regression models studying the effect of AC on death. Nonparametric survival analysis was conducted, and Kaplan Meier curves were constructed.
Results: Increased mortality was associated with therapeutic AC [OR 3.42 (2.06, 5.67)]. The log-rank test was statistically significant at p = 0.001 showing higher mortality for patients treated with therapeutic AC compared to prophylactic AC. Subset analysis of critically ill and intubated patients had similar survival curves regardless of AC dose. The log-rank test was not significant even with Prentice modification. For non-ICU patients, the log rank test favoring prophylactic AC disappeared when the analysis was stratified by D-dimer level less or greater than 3 μg/mL. Approximately 9% of patients receiving therapeutic AC experienced clinically significant bleeding or thrombocytopenia, versus 3% in those receiving prophylactic AC.
Conclusions: In our cohort, therapeutic anticoagulation provided no mortality benefit over thromboprophylaxis, independent of co-morbidities or disease severity. More adverse events were observed with therapeutic AC.
. 2020 Nov 5;197:65-68.
doi: 10.1016/j.thromres.2020.10.031. Online ahead of print.
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort
Lei Lynn[SUP] 1 [/SUP], Juan A Reyes[SUP] 2 [/SUP], Katrina Hawkins[SUP] 3 [/SUP], Arjun Panda[SUP] 4 [/SUP], Laura Linville[SUP] 4 [/SUP], Walaa Aldhahri[SUP] 4 [/SUP], Ghazal Kango[SUP] 5 [/SUP], Sneha Shah[SUP] 4 [/SUP], Shant Ayanian[SUP] 5 [/SUP], Karolyn Teufel[SUP] 5 [/SUP]
Affiliations
- PMID: 33186849
- PMCID: PMC7644262
- DOI: 10.1016/j.thromres.2020.10.031
Abstract
Background: COVID-19 infection is associated with D-dimer elevations, high rates of thrombus formation, and poor clinical outcomes. We sought to determine if empiric therapeutic anticoagulation (AC) affected survival in COVID-19 patients compared to standard prophylactic AC.
Methods: Retrospective analysis of 402 COVID-19 patients hospitalized between March 15 and May 31, 2020 was performed. Clinical outcomes were compared between 152 patients treated with therapeutic AC to 250 patients on prophylactic AC. An elastic net logistic regression was designed to first identify the important variables affecting mortality. These variables were then included as covariates to AC in standard multivariate logistic regression models studying the effect of AC on death. Nonparametric survival analysis was conducted, and Kaplan Meier curves were constructed.
Results: Increased mortality was associated with therapeutic AC [OR 3.42 (2.06, 5.67)]. The log-rank test was statistically significant at p = 0.001 showing higher mortality for patients treated with therapeutic AC compared to prophylactic AC. Subset analysis of critically ill and intubated patients had similar survival curves regardless of AC dose. The log-rank test was not significant even with Prentice modification. For non-ICU patients, the log rank test favoring prophylactic AC disappeared when the analysis was stratified by D-dimer level less or greater than 3 μg/mL. Approximately 9% of patients receiving therapeutic AC experienced clinically significant bleeding or thrombocytopenia, versus 3% in those receiving prophylactic AC.
Conclusions: In our cohort, therapeutic anticoagulation provided no mortality benefit over thromboprophylaxis, independent of co-morbidities or disease severity. More adverse events were observed with therapeutic AC.